Pankomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | tumor specific glycosylation of MUC1 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| Synonyms | PankoMab-GEX, anti-TA-MUC1 |
| ChemSpider | none |
PankoMab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] PankoMab is being developed by Glycotope GMBH [2] and is currently undergoing a phase II clinical trial for ovarian cancer [3]
References
- ↑ http://www.cancer.gov/drugdictionary?cdrid=687630
- ↑ https://www.glycotope.com/pipeline/pankomab-gex
- ↑ http://clinicaltrials.gov/ct2/show/NCT01899599
This article is issued from Wikipedia - version of the 11/19/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.